Tag: distribution agreement
Company News: Curetis and Laboratorios LETI Sign Exclusive Distribution Agreement for Unyvero™ in Spain and Portugal
– Five-year agreement based on extensive health economic assessment –
Curetis AG today announced that the company has closed an exclusive distribution agreement in Spain and Portugal with Laboratorios LETI, which includes all existing and future Unyvero™ instruments and consumables. LETI is a biopharmaceutical company based in Tres Cantos, near Madrid, Spain. Its diagnostics business unit distributes and markets a broad portfolio of in vitro diagnostics (IVD) and research products, among other offerings.
The agreement, effective January 1, 2014, was finalized following positive market feedback and favorable outcome of a joint, extensive health economic assessment which included four major hospitals in Spain and Portugal. The commercial launch of Unyvero™ in this region is expected in the first quarter of 2014.
For the implementation, Curetis will provide Unyvero training, marketing materials and supporting health economic research. LETI will manage all marketing and sales activities as well as storage and logistics support. The partners are targeting a market share of more than 50 percent of relevant hospitals and ICU units in the region within the next five years.
Company News: Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands
– Partners prepare market launch and clinical evaluation project –
Holzgerlingen, Germany, September 26, 2012 — Curetis AG today announced that Curetis and Mediphos have closed an exclusive distribution agreement for the Netherlands. Mediphos is an experienced independent distributor with a clear focus on molecular diagnostics and an emphasis on microbiology-based applications.
Under the agreement, both companies will prepare the market roll-out of Curetis´ Unyvero™ Solution and the Unyvero™ P50 Pneumonia Application. Moreover, Mediphos will be responsible for a clinical evaluation project in the Netherlands and will present the Unyvero Solution™ at the autumn meeting of the National Microbiology Association (NVVM) on November 15, 2012.
The Dutch target market for the Unyvero™ Solution covers approximately 40 hospitals (both university and large general hospitals). Significant market research has been jointly conducted by the partners to define a clear-cut execution strategy. Positive feedback from clinical opinion leaders and major hospitals has led to a two-pronged approach: while all target hospitals will be approached in parallel, the first Unyvero™ instrument system will be placed at one of the country’s leading university hospitals where a clinical evaluation by clinical opinion leaders will be initiated right away.